Intellikine Appoints William Rohn to its Board of Directors
LA JOLLA, Calif., Feb. 23 /PRNewswire/ — Intellikine, Inc., a leader in the development of drugs against the PI3K/mTOR pathway, today announced that William R. Rohn has joined the company’s board of directors.
Mr. Rohn has over 30 years of management experience in the biotechnology and pharmaceutical industry, including more than 10 years in executive management positions at IDEC Pharmaceuticals and Biogen Idec, where he served as Chief Operating Officer until his retirement in 2005. He joined IDEC in 1993 as Senior Vice President, Commercial and Corporate Development, was appointed Senior Vice President, Commercial Operations and was promoted to Chief Operating Officer in 1998. In 2002, he became President, responsible for Sales, Marketing, Business Development, Manufacturing, Quality, Medical Affairs and CMC Regulatory Affairs. He was responsible for building IDEC’s commercial infrastructure to support the launch of Rituxan, the first monoclonal antibody approved in the U.S. for the treatment of cancer. Mr. Rohn serves on the boards of directors of Elan Corporation, plc, Cerus Corporation, and Cebix, Inc.
“We are delighted to welcome Bill Rohn to Intellikine’s board of directors,” said Troy Wilson, Ph.D., J.D., President and CEO of Intellikine. “His strategic insights and experience in growing biotechnology companies, including his experience transitioning IDEC from a development stage company to a very successful commercial enterprise, will be invaluable to Intellikine as we seek to advance our growing pipeline of drugs against the PI3K/mTOR pathway.”
“Intellikine has rapidly built one of the best pipelines against the PI3K/mTOR pathway,” said William Rohn. “I am excited about the opportunity to work with the management team and board to build the company and, in particular, to forge industry-leading partnerships to develop and commercialize the company’s products for the treatment of cancer, inflammation and other serious diseases.”
Intellikine is a private, clinical-stage company focused on the discovery and development of innovative small molecule drugs targeting the PI3K/mTOR pathway. Intellikine recently announced the start of a Phase I trial for INK128, a selective TORC1/2 inhibitor for oncology and is advancing INK1197, a PI3K-delta/gamma dual-selective inhibitor for the treatment of inflammatory and respiratory diseases. Other programs include PI3K-delta/gamma dual-selective inhibitors for oncology, PI3K-alpha/beta selective inhibitors for oncology, as well as other isoform-selective inhibitors. Intellikine has raised $41 million from an outstanding group of life science investors including Abingworth, Sofinnova Ventures, CMEA Capital, Novartis Venture Funds, U.S. Venture Partners, Biogen Idec and FinTech Global Capital. In addition, Intellikine has a commitment, subject to fulfillment of certain conditions, for another $22.5 million in equity financing from its current investors. For more information, please visit the company’s website at www.intellikine.com.
SOURCE Intellikine, Inc.